Human Antibodies Targeting CD38 for Hematological Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective and specific targeting of CD38-positive cells, such as malignant cells, due to limited specificity and cross-reactivity with human and non-human species, which hampers therapeutic efficacy in conditions like multiple myeloma and leukemia.
Innovation Solution
Development of human or humanized antibodies with specific antigen-binding regions, particularly the H-CDR3 and L-CDR3 regions, that bind with high affinity to CD38, enabling targeted killing of CD38-positive cells through mechanisms like ADCC and CDC, while maintaining minimal cross-reactivity with non-target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target CD38-positive cells, then treatment is provided for conditions like multiple myeloma and leukemia, but the therapies lack effective specificity and cross-reactivity with human and non-human species, hampering therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody structure, specifically the CDR3 regions of both heavy and light chains, to achieve enhanced binding affinity and specificity for human CD38. The antibody sequence parameters were carefully selected and modified to improve therapeutic efficacy while maintaining species-specificity, resolving the contradiction between reliability and manufacturing precision.
2Reliability
If antibodies with high affinity for CD38 are developed, then targeted killing of CD38-positive cells is achieved, but cross-reactivity with non-target cells must be minimized to reduce toxicity
Solution Approach 1:
The patent applies local quality by focusing modifications on specific local regions of the antibody molecule, namely the CDR3 regions of the heavy and light chains. These localized changes enhance binding affinity for CD38-positive cells while maintaining selectivity and reducing cross-reactivity with non-target cells, thereby achieving targeted killing with minimal toxicity.
Solution Approach 2:
The patent uses copying by creating a highly specific antibody model based on the CD38 antigen structure. The antibody sequence was designed and optimized to precisely match the CD38 epitope, enabling selective binding and killing of CD38-positive cells while avoiding off-target effects through accurate structural correspondence.
3Manufacturing precision
If human or humanized antibodies are designed with specific antigen-binding regions, then specificity and affinity for CD38 are enhanced, but the complexity of antibody engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody engineering process into distinct modular components: the heavy chain variable region, light chain variable region, and specifically the CDR3 regions of each. This modular approach allows for targeted optimization of specificity and affinity in the CDR3 regions while using standardized frameworks for the rest of the antibody structure, thereby managing engineering complexity.
Data Source
AI summary
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.